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ETHICAL ACCEPTABILITY OF USING GENERIC CONSENT FOR 
SECONDARY USE OF DATA AND BIOLOGICAL SAMPLES IN 
MEDICAL RESEARCH
 
Ana Frunză1, Antonio Sandu2
Abstract: The research idea starts from the previous identification of certain elements of generic consent for research activities 
found in informed consent (IC) forms used in therapeutic activities in hospitals that have the right to conduct medical 
research on human subjects in Northeast Romania. The paper questions the ethical acceptability of secondary use of data and 
biological samples in medical research, in the context of obtaining generic therapeutic consent from patients. The objective 
of the research is to analyze the Romanian context of using the IC obtained in therapeutic purposes as a starting point for 
the research activity. We wish to argue that the practice of obtaining a generic consent - for using the data obtained and 
the biological samples collected in the therapeutic process for secondary analysis - raises serious ethical issues regarding the 
validity and effectiveness of the IC. 
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Aceptabilidad ética de usar consentimiento genérico para uso secundario de datos y de muestras biológicas en 
investigación médica 
Resumen: La idea de este estudio proviene de la identificación previa de ciertos elementos de consentimiento genérico 
para actividades de investigación, que se encuentran en formularios de consentimiento informado usados en actividades 
terapéuticas en hospitales que tienen la potestad de realizar investigación médica con sujetos humanos en el Noreste de 
Rumania. Este estudio cuestiona la aceptabilidad ética del uso secundario de datos y muestras biológicas en el contexto de 
obtener consentimiento genérico de pacientes en terapia. El objetivo de esta investigación consiste en analizar el contexto en 
Rumania al usar consentimiento informado en terapia como punto inicial de actividad de investigación. Argumentamos que la 
práctica de obtener consentimiento genérico —para usar los datos obtenidos y las muestras biológicas recolectadas en el proceso 
terapéutico en análisis secundario— preocupa éticamente respecto de la validez y efectividad del consentimiento informado.
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Aceitabilidade ética do uso de consentimento genérico para uso secundário de dados e amostras biológicas em 
pesquisa médica
Resumo: A ideia de pesquisa tem sua origem a partir da identificação anterior de certos elementos do consentimento genérico 
para atividades de pesquisa encontrados em formulários de consentimento informado (CI) usados em atividades terapêuticas 
em hospitais que têm o direito de realizar pesquisa médica em seres humanos no nordeste da Romênia. O artigo questiona 
a aceitabilidade ética de uso secundário de dados e amostras biológicas na pesquisa médica, no âmbito da obtenção do 
consentimento genérico terapêutico de pacientes. O objetivo da pesquisa é analisar o contexto romeno do uso do CI obtido 
por fins terapêuticos como ponto de partida para a atividade de investigação. Nós gostaríamos de argumentar que a prática de 
obter um consentimento genérico - para utilizar os dados obtidos e as amostras biológicas coletadas no processo terapêutico 
para análise secundária - levanta sérias questões éticas a respeito da validade e da eficácia do IC.
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Introduction
The paper starts from the identification of certain 
elements of generic consent for research activities, 
found in the Informed Consent (IC) forms used 
in therapeutic activities, in hospitals that have the 
right to conduct medical research on human sub-
jects in North-East Romania. 
In a brief analysis of hospitalization forms from a 
public clinical recovery hospital, we noticed that 
the hospitalization forms included a number of 
informative paragraphs with role of IC for poten-
tial future medical researches on human subjects.
The objective of the research is to analyse the ethi-
cal acceptability using the IC obtained in thera-
peutic purposes as a starting point for the research 
activity. 
In the scientific literature, there are controversies 
in using the data collected in the therapeutic pro-
cess in further research activities in at least 3 situa-
tions: 1) without the need for IC (for research); 
2) Broad Consent; 3) the need for research IC, 
separate from the therapeutic IC. 
We are interested in whether or not a broad for-
mulation of IC could be ethically used for allowing 
the conducting of research and for further publi-
cation of the resulting data.
We argue that, in the Romanian context, the prac-
tice of obtaining a mixed IC for using the data 
obtained and the biological samples collected in 
the therapeutic process for secondary analysis rai-
ses serious ethical issues regarding the validity and 
effectiveness of the IC. 
Meanings of consent in literature
The essence of the therapeutic IC is such that the 
patient gives the medical staff permission to per-
form an intervention relevant to his/her health 
condition(1). Proper respect for the patient’s auto-
nomy requires an ethical approach to the process 
of gaining the IC, sensitive to the way in which 
the patient understands the situation and expres-
ses his/her consent in accordance to what he has 
understood. 
IC for research represents the process in which the 
participant of the research agrees to participate, 
after being informed about the procedures, risks, 
and benefits(2). 
The practice of gaining IC can be interpreted in 
a formalist manner by referring to strict rules of 
gaining IC and their formalization, turning the 
IC into an instrument of fulfilling the legal obli-
gations of respecting the patients’ rights. IC can 
be approached in a paternalist manner, the rules 
being transparent, offering to therapist the possi-
bility to manipulate the patient’s decision by pre-
senting the risks, benefits, and procedures(2). 
Starting from the scientific literature, we have 
identified 3 theoretical situations of ethical using 
of the data and the biological samples collected in 
the diagnosis and treatment process: without the 
need for express IC, BC, or specific IC. 
No need for consent for secondary use in future re-
searches of the data research and samples collected in 
therapeutic process.
The data and biological samples are already avai-
lable for the medical units; therefore, none of the 
patient’s rights are being harmed (co-ownership of 
data), and the patient cannot be exposed to a state 
altered from the current condition. 
The lack of need of such IC can be justified when 
the risks associated with the research are minimal 
or equal to those given by the therapeutic context 
with no additional difficulty for the patient. 
The manner of obtaining data makes the patient 
and the medical unit co-owners of such data, gi-
ving both parts the usage right. In the absence of 
an expressed mention of non-acceptance of data 
processing for research purposes, the agreement 
can be considered implicit, the hospital being one 
of the owners with disposal rights on the data and 
samples(3). 
There is another opinion which supports that an 
IC for secondary use of data is not necessary. Ac-
cording to this opinion, the IC for secondary use 
of data and biological samples can be included in 
the IC for therapeutic procedures(4,5). We con-
sider that this opinion could have been shared by 
the issuers of the IC forms we used for analysis 
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in our research, as long as the analysed IC forms 
request the patients to agree both with therapeuti-
cally intervention and. 
Broad Consent
The current literature offers multiple definitions 
on Broad Consent (BC). BC involves offering 
the individual the option of consenting to future 
research that has a specific context and content, 
rather than for a specific, individual research pro-
jects(6). Grady defines BC as being consent for 
an unspecified area of subjects of possible future 
research, whose content and process are at least 
known to the participant(7).
BC is mostly debated in the context of bio-
banks(8,10,6). In order to be accepted as “infor-
med”, there should be a new consent requested 
anytime the research frameworks are being modi-
fied. BC is not informed consent in the true sense, 
in the absence of the specific information referring 
to research(11-13).
Ploug & Holm (2015) use the idea of meta-con-
sent as being the interplay between the BC and 
Dynamic Consent(6). Dynamic Consent is an al-
ternative model of consent in which the patient 
has the possibility to inform on the use of data and 
biological samples through the means of an onli-
ne platform that is updated daily. The individual 
is offered the possibility of withdrawing his data 
from use in research he/she does not agree with. 
Considering that the term BC is used in asso-
ciation with biobanks, we prefer to consider the 
specific of wide formulating of consent for future 
use of data through the term reminded by Onara 
O’Neil(14) – generic consent. 
The need for research IC that is separate from the 
therapeutic IC
Obtaining consent implies a process; Beauchamp 
& Childress(15) set out a series of 7 components 
of the process of gaining informed consent. 
The elements of disclosure (preconditions): (1) 
competence in understanding and making deci-
sions; (2) voluntary decision; 
The elements of information: (3) the disclosure 
(the material information); (4) the recommenda-
tion (of a plan); (5) understanding (in disclosure 
and recommendation); 
Elements of consent: (6) the decision (in favour 
of the plan); (7) the authorization (of the chosen 
plan). 
Grady shows that the process of gaining IC in-
volves a series of multiple elements, including 
disclosure, understanding, voluntary choice, and 
authorization. 
An argument in favour of the need for separating 
the research IC from the therapy IC is to avoid the 
Therapeutic Misconception(16), since obtaining 
the consent from the participation to the research 
differs from the IC for therapy(17). The patient 
will be influenced to consider that the research 
is directly oriented towards his/her own good 
and not the common good for knowledge deve-
lopment in medicine. Research may not involve 
specialized care: giving placebo medication to a 
patient whom is withdrawn the basic treatment 
might endanger the health condition maintained 
by the classic medication. 
Consent references within Romanian Legal Fra-
mework
IC is regulated by Law no. 46, from January 21, 
2003, on the patient’s rights, updated on May 20th, 
2015, in Chapter 3, Patient’s consent on medical 
intervention. This chapter refers to the procedure 
of gaining IC both for medical intervention, and 
in the context of involving the patients in didactic 
activity and medical research(18). The legislation 
does not expressly require a standard form of IC, 
but the practice makes all medical units apply their 
own IC form introduced to the patients in the ad-
mission forms, even before diagnosis. Patients are 
rarely presented IC forms during hospitalization, 
especially when there are complicated medical in-
terventions. The IC form is standardized in some 
situations, being available for download on the 
medical institution’s website with blanks for filling 
in the patient’s identification and/or diagnosis/
therapeutic procedures that are recommended or 
are to be refused. 
The forms automatically include data on the 
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patient’s consent, so that the information and 
samples collected in the process of diagnosis and 
therapy can be used in further research activities. 
Methodology 
First, we performed content analysis on a series of 
IC forms, following the identification of situations 
in which the patients are asked to sign IC forms 
for therapy and automatically involve themselves 
in future potential medical research of which the 
purpose, specifics, benefits, or risks are not made 
known to them. 
For the current paper, we analysed 11 forms 
and we selected the most relevant content to be 
brought into discussion. 
We gave up on similar expressions identified in 
different forms, making sure not to eliminate in-
formation that is different, regardless of whether 
they support the paper’s thesis or not. The forms 
selected in order to be considered in the analysis, 
upon reading all collected, are given by abbrevia-
tions, as follows: 
IC1 –patient’s consent for chemotherapy
IC2 –patient’s consent for surgical intervention
IC3 – IC fragments introduced in the content of 
the hospitalization forms – ENT department.
IC10 – patient’s consent on the methods of diag-
nosis, therapy, anaesthetics and surgery
IC11 – patient’s consent on the investigations, 
therapeutic procedures, for participation in the 
medical educational process and respecting the in-
ternal rules for the hospitalized patients
After analysis of the IC forms, we continued the 
research by conducting in-depth interviews with 
doctors, medical assistants, and decision makers in 
the medical system, namely members of the EC. 
The interviews’ purpose was to identify how the 
Informed Consent (IC) is understood by profes-
sionals in the medical field, particularly in the 
medical care institutions in Iasi (North-eastern 
city in Romania). We were interested in identi-
fying whether the medical staff that applies IC as 
an ethical tool have knowledge – and are willing 
to apply it in their daily practice – of the bioethi-
cal principles which should underlie the adoption 
and implementation of such a tool. 
A series of questions expressly targeted the attitude 
of the respondents on using the data obtained in 
the process of diagnosis and treatment in further 
research and considering the generic consent as a 
legitimate form of consent in research. 
Participants & Data Collection 
The participants were 10 medical representatives 
(doctors, managers, chairs of ECs, nurses) of Ro-
manian medical institutions (Iasi city) who are 
allowed to conduct medical research on human 
subjects.  The sampling was carried out by the 
snowball method while respecting the affiliation 
of the respondents to institutions selected as sub-
jects for our research. The respondents were aged 
between 28 and 60 years; five respondents were 
male and five were female. As specific criteria of 
inclusion we considered whether the potential res-
pondents had published scientific research results 
for medical research conducted within the selec-
ted institution in the last five years. We identified 
medical staff other than physicians—for example, 
nurses, psychologists, etc.—and we included them 
in the sample. We included at least two hospital 
directors in the sample. 
The data were collected between March and June 
2016; The interviews followed a previous content 
analysis of a series of IC forms collected from me-
dical institutions from Iasi; 
Limits of the Research 
The results and conclusions could be extended to 
other contexts in which BC is used to justify the 
use of data obtained in the therapeutic process for 
further research activities. 
The research is tributary to a social-constructionist 
paradigm, which allows a certain degree of subjec-
tivity in the analysis of the qualitative data. This 
might bring criticism regarding the contamina-
tion of the analysis of data with the investigators’ 
subjective opinions. In order to diminish the pos-
sible influences, methodological triangulation was 
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used by analysing both the IC forms and the data 
obtained by interview, both in the coding process, 
and in the analysis one. 
Informed consent forms analysis 
The content of the IC forms is mostly oriented 
towards the therapeutic intervention; references to 
the research part are sporadic, failing to ensure the 
real quality of consent for medical research. From 
the perspective of voluntary participation in the 
research activity connected to the therapeutic one, 
interferences between the IC for intervention or 
treatment, and IC for medical research were iden-
tified. With regard to these interferences, we con-
sider it necessary to bring into discussion certain 
possible ethical risks. 
Generic Consent & the Quality of Medical Care
Into the analysed forms, the possibility of refusal 
to participate in the research is not specified and 
neither are any references to the patient being in-
formed regarding the nature and future objectives 
of the research. The only reference to the doctor’s 
obligations, from the perspective of the research, 
is of non-maleficence. The principle of beneficen-
ce is excluded and that of autonomy is partially 
violated. The formulation of the majority of the 
IC forms we analysed violates the categorical im-
perative. Although the therapy is oriented towards 
the patient, the elements of IC in the research di-
gress from it, wrongly considering that the simple 
non-maleficence justifies the ethical nature of any 
future research. 
The real nature of the IC document does not ari-
se, which does not refer to the patient’s requested 
contribution to the scientific research and medical 
education, nor the fact that it was made clear for 
the patient. 
What is more, introducing non-specific consent 
might influence the patient to believe in the ab-
sence of his/her participation in the research ac-
tivity required, or will determine the absence of 
therapy. 
The criteria of exclusion of certain therapeutic 
procedures do not expressly formulate the possi-
bility of refusal to participate in research activity. 
From an ethical perspective, it can be interpreted 
as an abuse of the dominant position of the doctor 
in front of the patient. 
The same situation of uncertain consent can be 
found in the authorization of filming or photo-
graphing different parts in medical or scientific 
interest. Even though it is referred to the obliga-
tion of blurring the elements of physiognomy, this 
is in order to alleviate the patient’s stress and in-
crease his/her trust in the physician, the expressed 
incapacity of refusal being able to create confusion 
with respect to his/her dignity. 
(IC1) (…) I authorize / (IC2) I consent (TO) 
the photographing or filming the body or diffe-
rent parts of it for medical or scientific purpose, 
but the doctor is obliged to mask the essential ele-
ments of the physiognomy that could lead to my 
identification (…)
The same situation of uncertain consent can be 
also found in the authorization for filming or pho-
tographing different parts of the body with medi-
cal or scientific purpose. The expressed impossibi-
lity of refusal to be photographed or filmed may 
create confusion regarding the respect for dignity. 
Consent for Harvesting, Storage, and Use of All 
Biological Products
The assent of the subject regarding the use of “all 
biological products taken” is given in order to “es-
tablish the diagnosis or treatment”, and not for its 
use in order to conduct scientific research. 
The implicit assent is not in favour of using the 
biological samples in research activity, for which 
the patient does give his/her assent for participa-
tion.  
(IC2), (IC7) “I consent and explicitly express my 
agreement to the harvesting, storage, and use of all 
biological products taken from my body, in order to 
establish the diagnosis or treatment.” (IC10, para-
graph 7)  
Although reproduced in the form in reverse or-
der, in the previous paragraph, (IC10, paragraph 
6) “tissues or parts of organs surgically removed can 
be examined in medical, scientific and educational 
purposes”, we can interpret that as any biological 
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sample can be used in further research, in any pos-
sible form. 
Mandatory Consent & Possible Experiments 
on Human Subjects
(IC10, paragraph 9) “During hospitalization, there 
are situations in which passive participation in cli-
nical medical education and scientific research can 
be involved, the only final purpose is the benefit and 
interest of the patients”.
This formulation could be interpreted as impli-
citly authorizing some experiments on human 
subjects without specific consent, as long as it hap-
pens during the patient’s hospitalization. The de-
clared purpose of the participation in the research 
it might be considered into the interest and bene-
fit of the patients, but without it being explained.
Currently, the medical research is performed for 
the benefit of future patients – in the spirit of res-
ponsibility for the patients that are not present, 
including those belonging to future generations – 
and not necessarily for the immediate benefit of 
current, direct patients. The lack of delimitation 
of benefits and beneficiaries of the research might 
lead to misunderstanding and error in consent 
(therapeutic misconception). 
Generic Consent & DNA Analysis 
The formulation in (IC10) makes no reference to 
whether a possible clinical trial is being conside-
red: for example, a study of phase III of testing 
certain innovating medicines, or whether it only 
refers to the observation of the patient’s stages of 
evolution.
“The biological material harvested (blood, tissues, or-
gans) in diagnosis purposes can also be examined in 
scientific research purposes (including DNA analy-
sis), training, it can be photographed and published 
without my express consent, keeping the confidentia-
lity.” (IC10), (IC3)
We consider that in order to consent to a pro-
cedure of scientific research which implies, for 
example, DNA analysis, the subject should at least 
understand what benefits this analysis could bring 
him/her. Some subjects may concur with the idea 
according to which the human genome should be 
in the immaterial, intangible heritage of humani-
ty, and that no experiments should be conducted 
on our own genome and will, therefore, refuse the 
generating of data about their own DNA. 
The patient may legitimately consider that beyond 
the simple medical data analysis, its biological evi-
dence, including the DNA sample, can be subject 
to advanced research, for example, that referring 
to the generating of stem cells, from organic tis-
sues or DNA manipulation. A suspicious subject 
may extrapolate this information and raise ques-
tions regarding the preservation of tissues in the 
medical institution, which receives the authoriza-
tion or different transfers for research purposes to 
other medical institutions, which have the capaci-
ty for research in the genetic field. 
Another ethical risk of using wide IC for research 
(generic consent) is: 
(IC11) “The harvested biological material (blood, 
tissue or organs) for the purpose of diagnosis, can 
also be expressed in other areas of scientific research, 
and can be photographed and published without any 
other explicit authorization from me, preserving the 
confidentiality”. 
This can create a false impression of harvesting 
for the purpose of diagnosis, the harvesting that 
might have research as a sole purpose and that, 
eventually, would endanger the patient’s life. 
“(…) I authorize the photographing or filming of my 
body or different parts of it in medical or scientific 
purposes, but the doctor is obliged to mask the essen-
tial elements of my physiognomy that might lead to 
my identification (…).” (IC1), (IC10)
“I also agree to be photographed and I agree that the 
photos can be published in scientific medical jour-
nals.” (IC3)
Findings from interviews
IC for research versus IC for therapy
The most respondents are aware of the need for a 
different IC for the research activity. 
“In research, things are more detailed, but it is a di-
fferent activity. The research activity is with volunteer 
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subjects that accept to come, the terms are totally di-
fferent and are made in the spirit of the companies 
that sell a particular product, (…) The IC, when I 
started working, had 2 pages, and now it has 20.” 
(I04)
“In the clinical studies there is a rather long docu-
ment.” (I06)
We can observe in I04’s discourse that the IC is 
still seen as a form that “had 2 pages” and it has 
subsequently increased to 20; the respondent rela-
tes to the simple IC form, neglecting the process 
of gaining the IC. What is more, the respondent 
draws the attention that the forms “are made in 
the spirit of the companies that are selling a pro-
duct”, not of a team that implements research, but 
the company that finances it. The correct proce-
dure would be that the research team to propose 
the protocol, which implicitly contains the IC, to 
the IRB for evaluation and approval. The finan-
cing company should not be involved in the pro-
tocol since it represents an interested third party, 
whose implication is able to generate a conflict of 
interest. 
In the data analysis, we have identified references 
to possible abuse of the dominant position of the 
doctor and the medical institution (teaching hos-
pital): 
“It is presumed that the patient knows the functions 
and the specifics of the hospital (teaching hospital) 
and his/her arrival to such hospital anticipates the 
presumption that he knows what is going on, accep-
ting to participate to the specific actions of the hospi-
tal (therapeutic, didactic, research)” (I03)
It is assumed that signing the IC is just a formality, 
the agreement being already implicit. This leads to 
the vulnerabilization of the patient, who is put in 
difficulty to refuse the participation to research. 
This aspect becomes even of greater importance 
since the IC forms are usually signed in the ad-
mission process, before any other procedure, in-
cluding diagnosis, to be done.
“(In research) there are stipulated all aspects, risks, 
benefits, procedures, how many visits will there be, 
how many times, how long will the interview take, if 
they have the right to eat, if the doctor will be paid, 
that you can report them, there are introduced cases 
of malpractice of the sponsor and the investigator. It 
means it is more comprehensive.” (I04)
The respondents show that a research IC is more 
detailed, with more comprehensive information 
regarding the risks, benefits, procedures etc. On 
the other hand, the IC for therapy: 
“(…) is an informed consent with providing data, of 
maximum 3 pages (in medical practice)” (I04)
We again observe the strict administration relating 
to the IC, identified in number of pages, the infor-
mation technicality, but without reference to the 
real ethical reflection. 
Blurred Consent – Can IC Generate Misunders-
tanding and Misconception? 
The doctors interviewed make the distinction 
between the IC for research through invasive pro-
cedures and the need for voluntariness and non-
invasive procedures (I01). There are respondents 
that consider there is no difference between the IC 
for research and that for medical practice. 
“No, I don’t see any difference. The consent is a con-
sent, be it therapeutic or for research. But the research 
in the area of clinical studies is also treatment. We are 
in the common denominator.” (I02)
The common denominator between the medical 
practice and the medical research becomes the IC. 
The respondent considers medical research an ad-
vanced form of individual therapy in the benefit 
of the patient. The confusion seen in doctors can 
be transferred to the patient, especially when BC 
is requested the by the very IC form for therapeu-
tic intervention. 
Later, as the interview performs, the respondent 
tints his statements: 
“At first, I was telling you that obtaining IC in medi-
cal practice is no different than in research on human 
subjects, but methodologically, there is a difference. 
Practically, in clinical studies they work more, sin-
ce the degree of suspicion on clinical studies is much 
higher.” (I02)
This might suggest the lack of a preliminary re-
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flection on the ethical role of IC, and the inter-
view itself offers an opportunity for reflection. The 
ethical reflection can be considered peripheral, the 
lack of it being justified by the overload of the 
doctor with administrative situations, of actual 
practice, medical emergencies, the pressure of the 
lack of human resources, and of time. 
In some cases, the difference between the IC for 
therapy and that for research is nuanced, from the 
perspective of the clarity of information offered 
through the IC form. The lack of clarity in the IC 
for therapy is attributed to the abundance of the-
rapeutic procedures, of possible effects, etc., which 
cannot all be contained in one form. 
“Absolutely (I see a difference between the IC for me-
dical practice and that in clinical trials)! They cannot 
be compared. This one, from the medical practice, is 
very brief. It only has some references to what is about 
to happen: the procedure, treatment, information on 
possible side effects, but it is not a very clear one (…)” 
(I06) 
The criteria for differentiating the two types of 
IC, identified by the respondents, are either the 
dimension of the forms, or the clarity of informa-
tion, without taking into consideration the exis-
tence of an overlap between therapy and research 
in the IC form. 
Discussions and recommendations  
We argue that, in the Romanian context (North-
Eastern region), the practice of gaining a wide IC 
for using data and biological samples collected in 
the therapeutic process for secondary analysis, rai-
ses serious ethical issues regarding the validity and 
effectiveness of the IC. The model of the mix of 
consent was analysed by using generic consent for 
research included in the IC for therapy. 
We consider necessary that the persons performing 
medical research to be able to make the distinction 
between the situations in which the IC is requi-
red and then be able to acknowledge, describe for 
IRB, and apply the process of obtaining the IC. 
In an international context, such a separation is 
regulated through institutional ethics policies that 
can delimitate the specifics of the researchers that 
expressly require IC. We do not deny the fact that 
there can be research that would use a retrospecti-
ve reconsideration of certain data collected in the 
therapeutic process, for example in documenting 
new diseases, and the reclassification of certain 
cases previously diagnosed as belonging to a par-
ticular disease, are situations in which we find it 
necessary to use data previously collected, based 
on a potential generic consent. 
We cannot agree with the use of collected samples 
and data without the request of a specific consent, 
even in the situation in which it is argued that 
such actions do not infringe upon any subjective 
right of the patient and cannot harm him/her. 
We find it necessary to have consent for secondary 
use of data, but we don’t see it connected to the-
rapeutic consent, since it leads to misconception, 
abuse of power etc. 
Introducing alternatives for obtaining the consent, 
such as generic consent, dynamic consent, meta-
consent (previously described in the article), by 
the regulation of the research institutions would 
facilitate their use in practice, only in the context 
in which there would be a real institutional or in-
dividual interest, for the ethics of research. In the 
countries, wherein the ethics of research is being 
pioneered, such as Romania, the use of wide con-
sent can be a legal cover that would not consider 
the ethical implications of practice and the possi-
ble risks for the subjects.  
In order to simultaneously satisfy, the need for 
consent in research of collected data and biologi-
cal samples and respect the right to be informed, 
to autonomously express the will on the use of 
data, reducing the risk of misunderstanding or 
compulsory consent can be fulfilled through the 
use of a wide consent, such as meta-consent. Me-
ta-consent aims to approve the secondary use of 
data and biological samples, and is signed after the 
procedures, diagnosis, and treatment, upon relea-
se or after since it is a separate form and expressly 
destined to a research activity. 
In the case of patients in the terminal phase, the 
use of data and biological samples collected and 
preserved can only be done after obtaining the 
consent of the caregivers. No research activity 
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should be possible by involving the hospitalized 
patients based on wide consent, but only based on 
IC for research. The research should be conducted 
as much as possible after the therapeutic activity, 
or when they are enrolled in the studies, with fully 
informing them with regard to the nature of the 
research, risks, benefits etc. 
We recommend that the Romanian legislation, 
but also that of other states in which the ethics of 
research is at an early stage, to establish an ethics 
policy of separating the wide research consent 
from any form of consent for therapy. The obtai-
ning of the research consent should not be done 
by the team that performed the therapy, and not 
before the end of the period of therapy.
We also recommend conducting extensive ethical 
training programs addressed to the medical per-
sonnel conducting research activities, but also to 
those involved in the development of ethical po-
licies. 
The analysis of the IC forms and data collected 
through interviews lead to a few appreciations 
referring to the wide use of IC as an instrument 
of legal justification of the medical activity and of 
research, and less as an instrument of ethical re-
flection. 
We can characterize the procedure of gaining con-
sent as being “blurred consent”, since, according 
to the examples of IC we analysed, the patient 
cannot clearly understand what he is consenting 
to and the limitations of the consent, regarding 
the use of data and collected samples. From the 
analysed forms emerges no concern of those im-
plicated in the ethics policy of the institutions, 
regarding the promotion of patients’ autonomy, 
reducing the role of the consent to its administra-
tive function. What is more, not even the inter-
viewed doctors, belonging to institutions with the 
right of medical research, have no obvious ethical 
reflection, referring to the limitations of involving 
patients in the research or the promotion of their 
autonomy. 
We consider that using a mixed IC form that com-
prises both the agreement for therapeutic practi-
ce and that for research (present and future) is, 
at least, questionable from the perspective of the 
abuse of a dominant position in the medical insti-
tution. The use of BC elements is connected to the 
quality of the medical act, extending the legitima-
te limits of consent for intervention and transfor-
ming the IC into generic consent, including the 
collection, storage and use of data and biological 
samples. Applying the IC form, even before the 
diagnosis and therapy procedures, transforms the 
IC into mandatory consent, since the vulnerable 
patient can have difficulty in establishing the li-
mitations of the consent, or if the absence of the 
acceptance to use the data for research can jeopar-
dize the quality of the therapeutic act. 
Conclusions
The forms analysed contain references to the 
implicit consent of the patient to participate in 
activities with a research nature that were not 
specified. There were cases in which this generic 
consent approach has generated situations of risk 
to the patient by correlating the “blurred” gene-
ric consent with particular situations that lead to 
malpractice. 
The elements of generic consent are, in our opi-
nion, introduced illegitimately in the IC forms in 
order to allow for a secondary use of the given data 
obtained during the diagnosis and the patient’s 
therapy, especially after tissue sampling. The right 
to use the data obtained for research purposes du-
ring diagnosis or therapeutic intervention may 
transform the clinical, therapeutic act into illegi-
timate study on human subjects. 
The use of images obtained during diagnosis or 
treatment may lead to the patient’s vulnerability; if 
they knew those were being used for other purpo-
ses they may not have expressed their agreement. 
Both the agreement to participation in research, 
and to activities in medical education, should be 
requested separately, making them subject to a di-
fferent informed consent. In offering these types 
of IC, it should be clearly explained to the patient 
that the refusal to participate in the research or 
medical education would not endanger his/her 
access to adequate treatment for his/her health 
condition.
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